Authors
Don D Sin, Bruce E Miller, Annelyse Duvoix, SF Paul Man, Xuekui Zhang, Edwin K Silverman, John E Connett, Nicholas A Anthonisen, Robert A Wise, Donald Tashkin, Bartolome R Celli, Lisa D Edwards, Nicholas Locantore, William MacNee, Ruth Tal-Singer, David A Lomas
Publication date
2011/5/1
Journal
American journal of respiratory and critical care medicine
Volume
183
Issue
9
Pages
1187-1192
Publisher
American Thoracic Society
Description
Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum.
Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality.
Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study.
Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels …
Total citations
Scholar articles
DD Sin, BE Miller, A Duvoix, SFP Man, X Zhang… - American journal of respiratory and critical care …, 2011